The Journal of Immunology, Vol 153, Issue 10 4625-4635, Copyright © 1994 by American Association of Immunologists

ARTICLES

Inhibition of in vivo tumor growth by the beta chemokine, TCA3

J Laning, H Kawasaki, E Tanaka, Y Luo and ME Dorf
Department of Pathology, Harvard Medical School, Boston, MA 02115.

TCA3 is a proinflammatory murine glycoprotein that shares structural features with cytokines of the beta chemokine family and is a chemoattractant for neutrophils and monocytes. To assess the in vivo functions of TCA3, the cDNA was expressed in two mouse myeloma cell lines. Although the transfected and control cells had similar growth rates in vitro, TCA3-expressing tumors demonstrated impaired growth in both normal and immunodeficient mice. Histologic evaluation of the injection sites demonstrated that TCA3 expression resulted in an early neutrophil and monocyte infiltrate accompanied by tumor necrosis. There was complete regression of the TCA3-transfected tumor in some immunocompetent syngeneic mice. The TCA3-transfected cells induced specific and long-lasting immunity in mice that showed complete tumor regression; these animals were resistant to challenge with nontransfected tumor cells. In contrast, priming with irradiated tumor cells provided little protection against challenge with nontransfected tumor, which indicates that TCA3 specifically augments tumor immunogenicity. Mixing TCA3-transfected cells with normal tumor cells causes retarded growth of the normal tumor cells provided the latter are injected into the same site. Furthermore, direct in situ injection of soluble rTCA3 early during the course of tumor implantation also inhibits tumor growth. The data suggest that TCA3 may perform two roles in tumor protection: it induces lymphocyte-independent antitumor activity and stimulates tumor-specific immunity. We speculate that TCA3 has natural adjuvant activities that result in augmented immune responses.

This article has been cited by other articles:

				T. F. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261. [Abstract] [Full Text] [PDF]

				M. V. Lopez, S. K. Adris, A. I. Bravo, Y. Chernajovsky, and O. L. Podhajcer IL-12 and IL-10 Expression Synergize to Induce the Immune-Mediated Eradication of Established Colon and Mammary Tumors and Lung Metastasis J. Immunol., November 1, 2005; 175(9): 5885 - 5894. [Abstract] [Full Text] [PDF]

				P. A. Ruffini, A. Biragyn, M. Coscia, L. K. Harvey, S.-C. Cha, B. Bogen, and L. W. Kwak Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis J. Leukoc. Biol., July 1, 2004; 76(1): 77 - 85. [Abstract] [Full Text] [PDF]

				A Zafiropoulos, N Crikas, A M Passam, and D A Spandidos Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer J. Med. Genet., May 1, 2004; 41(5): e59 - e59. [Full Text] [PDF]

				J.-Q. Gao, Y. Tsuda, K. Katayama, T. Nakayama, Y. Hatanaka, Y. Tani, H. Mizuguchi, T. Hayakawa, O. Yoshie, Y. Tsutsumi, et al. Antitumor Effect by Interleukin-11 Receptor {alpha}-Locus Chemokine/CCL27, Introduced into Tumor Cells through a Recombinant Adenovirus Vector Cancer Res., August 1, 2003; 63(15): 4420 - 4425. [Abstract] [Full Text] [PDF]

				K. W. Christopherson II, J. J. Campbell, and R. A. Hromas Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration Blood, December 15, 2001; 98(13): 3562 - 3568. [Abstract] [Full Text] [PDF]

				K. Christopherson II and R. Hromas Chemokine Regulation of Normal and Pathologic Immune Responses Stem Cells, September 1, 2001; 19(5): 388 - 396. [Abstract] [Full Text] [PDF]

				J. Talkington and S. P. Nickell Role of Fc Gamma Receptors in Triggering Host Cell Activation and Cytokine Release by Borrelia burgdorferi Infect. Immun., January 1, 2001; 69(1): 413 - 419. [Abstract] [Full Text] [PDF]

				G. Bernardini, G. Spinetti, D. Ribatti, G. Camarda, L. Morbidelli, M. Ziche, A. Santoni, M. C. Capogrossi, and M. Napolitano I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo Blood, December 15, 2000; 96(13): 4039 - 4045. [Abstract] [Full Text] [PDF]

				K. Shiraishi, S. Fukuda, T. Mori, K. Matsuda, T. Yamaguchi, C. Tanikawa, M. Ogawa, Y. Nakamura, and H. Arakawa Identification of Fractalkine, a CX3C-type Chemokine, as a Direct Target of p53 Cancer Res., July 1, 2000; 60(14): 3722 - 3726. [Abstract] [Full Text]

				M. J. Frederick, Y. Henderson, X. Xu, M. T. Deavers, A. A. Sahin, H. Wu, D. E. Lewis, A. K. El-Naggar, and G. L. Clayman In Vivo Expression of the Novel CXC Chemokine BRAK in Normal and Cancerous Human Tissue Am. J. Pathol., June 1, 2000; 156(6): 1937 - 1950. [Abstract] [Full Text] [PDF]

				S. E. Braun, K. Chen, R. G. Foster, C. H. Kim, R. Hromas, M. H. Kaplan, H. E. Broxmeyer, and K. Cornetta The CC Chemokine CK{beta}-11/MIP-3{beta}/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells J. Immunol., April 15, 2000; 164(8): 4025 - 4031. [Abstract] [Full Text] [PDF]

				S. J. Ha, C. H. Lee, S. B. Lee, C. M. Kim, K. L. Jang, H. S. Shin, and Y. C. Sung A Novel Function of IL-12p40 as a Chemotactic Molecule for Macrophages J. Immunol., September 1, 1999; 163(5): 2902 - 2908. [Abstract] [Full Text] [PDF]

				C. S. Tannenbaum, R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton The CXC Chemokines IP-10 and Mig Are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor J. Immunol., July 15, 1998; 161(2): 927 - 932. [Abstract] [Full Text] [PDF]

				B. J. Rollins Chemokines Blood, August 1, 1997; 90(3): 909 - 928. [Full Text] [PDF]

				R. S. Roos, M. Loetscher, D. F. Legler, I. Clark-Lewis, M. Baggiolini, and B. Moser Identification of CCR8, the Receptor for the Human CC Chemokine I-309 J. Biol. Chem., July 11, 1997; 272(28): 17251 - 17254. [Abstract] [Full Text] [PDF]

				H. L. Tiffany, L. L. Lautens, J.-L. Gao, J. Pease, M. Locati, C. Combadiere, W. Modi, T. I. Bonner, and P. M. Murphy Identification of CCR8: A Human Monocyte and Thymus Receptor for the CC Chemokine I-309 J. Exp. Med., July 7, 1997; 186(1): 165 - 170. [Abstract] [Full Text] [PDF]